Avalo Therapeutics, Inc. · NASDAQ:AVTX
The Vanguard Group reported a 5.26% stake in Avalo Therapeutics, Inc. (Schedule 13G)
Event Sep 30, 2025 · Filed Oct 30, 2025
The Vanguard Group reported a 5.26% stake in Avalo Therapeutics, Inc., 692,637 shares, as a passive investor on Sep 30, 2025. Filed Oct 30, 2025 (Schedule 13G).
- Stake
- 5.26%
- Shares
- 692,637
- Intent
- Passive
- What changed
- Crossed above 5%
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| The Vanguard Group | 5.26% | 692,637 |
Source
Related
- Avalo Therapeutics, Inc.
- The Vanguard Group
- Avalo Therapeutics, Inc. shareholders
- Schedule 13G/A · The Vanguard Group · Jan 30, 2026
- Form 4 · Sullivan Christopher Ryan · Sep 18, 2026
- Form 4 · Sullivan Christopher Ryan · Sep 11, 2026
- Form 4 · Doyle Mittie · Sep 1, 2026
- Form 4 · Sullivan Christopher Ryan · Aug 19, 2026
- Form 4 · Doyle Mittie · Aug 19, 2026